Use the Back button in your browser to see the other results of your search or to select another record.
Sportizumab -- multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: a randomized controlled trial [with consumer summary] |
Proschinger S, Belen S, Adammek F, Schlagheck ML, Rademacher A, Schenk A, Warnke C, Bloch W, Zimmer P |
Brain, Behavior, and Immunity 2024 Feb;124:397-408 |
clinical trial |
This trial has not yet been rated. |
Copyright release for this abstract has not been granted.
|